FDA Approves New Powder Form of CF Drug TOBI®

The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).

March 25, 2013 | 1 min read

The FDA approved the new treatment for people with CF ages 6 and older who have P. aeruginosa and whose lung function (FEV1) is between 25 percent and 80 percent predicted.

According to the drug's manufacturer, Novartis, TOBI Podhaler shortens treatment time by about 70 percent, compared with nebulized TOBI.

TOBI Podhaler is administered with a pocket-sized inhaler, and does not require a nebulizer. TOBI Podhaler does not need to be stored in a refrigerator and does not require a power source to operate the inhaler.

Novartis said it anticipates TOBI Podhaler will be available in the United States in the second quarter of 2013.

P. aeruginosa is found in about half of all people with CF in the U.S. and is the leading cause of lung damage in those living with the disease.

Share this article
About the CF Foundation | Drug Pipeline | Antibiotics
Recent news
Cystic Fibrosis Community Perspectives Influence Future of CF Care Model
News | 4 min read
CF Foundation Adapts Registry Reporting to New Race-Neutral Standards
News | 5 min read
Nearly 350 Advocates Urge Congressional Action During 17th Annual March on the Hill
News | 3 min read
You might also be interested in...
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.